Cadrenal Therapeutics, Inc.
Business
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing novel therapies for life-threatening immune and thrombotic conditions. Its lead product, CAD-1005, is a first-in-class selective 12-lipoxygenase inhibitor in Phase 3 development for heparin-induced thrombocytopenia; the company also develops tecarfarin, a vitamin K antagonist for chronic anticoagulation in kidney disease and cardiac device patients, and frunexian, an intravenous Factor XIa inhibitor for acute care settings. Cadrenal operates through clinical-stage development and does not manufacture products, instead engaging contract development and manufacturing organizations for supply.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| General and administrative expenses | 9 | 7 | 4 | 2 | |
| Research and development expenses | 4 | 4 | 4 | 392,859 | |
| Depreciation expense | 6,874 | 1,880 | 1,980 | 1,266 | |
| Total operating expenses | 13 | 11 | 8 | 3 | |
| Loss from operations | −13 | −11 | −8 | −3 | |
| Interest and dividend income | 223,815 | 309,251 | −249,092 | −21 | |
| Total other income | 223,815 | 309,251 | 724,243 | 4 | |
| Net loss and comprehensive loss | −13 | −11 | −8 | −7 | |
| Net loss per common share, basic (in Dollars per share) | −6.64 | −8.73 | −9.29 | −0.85 | |
| Net loss per common share, Diluted (in Dollars per share) | −6.64 | −8.73 | −9.29 | −0.85 | |
| Weighted average number of common shares used in computing net loss per common share, basic (in Shares) | 2 | 1 | 899,465 | 8 | |
| Weighted average number of common shares used in computing net loss per common share, Diluted (in Shares) | 2 | 1 | 899,465 | 8 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-01-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 10 | 8 | 32,586 | — | |
| Interest receivable | 5,096 | 38,153 | 37,248 | — | — | |
| Prepaid expenses and other current assets | 200,140 | 42,257 | 52,425 | — | — | |
| Deferred offering costs | 106,342 | 14,445 | — | — | — | |
| Total current assets | 4 | 10 | 8 | 727,596 | — | |
| Property, plant and equipment, net | 5,174 | 6,944 | 2,287 | 1,013 | — | |
| Other assets | 2,167 | 3,792 | 3,792 | 5,987 | — | |
| Total assets | 4 | 10 | 9 | 778,174 | — | |
| Accounts payable | 650,663 | 2 | 167,319 | 404,897 | — | |
| Accrued liabilities | 937,319 | 1 | 638,206 | 863,564 | — | |
| Total current liabilities | 2 | 3 | 826,875 | 1 | — | |
| Total liabilities | 2 | 3 | 826,875 | 6 | — | |
| Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding as of December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.001 par value; 75,000,000 shares authorized, 2,338,127 shares issued and outstanding as of December 31, 2025; 1,782,486 shares issued and outstanding as of December 31, 2024 | 2,338 | 1,782 | 868 | 8,194 | — | |
| Additional paid-in capital | 42 | 33 | 23 | 1 | — | |
| Accumulated deficit | −39 | −26 | −15 | −7 | — | |
| Total stockholders equity | 3 | 7 | 8 | −6 | — | |
| Total liabilities and stockholders equity | 4 | 10 | 9 | 778,174 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Equity-based compensation | 2 | 1 | 710,381 | 928,049 | |
| Non-cash lease expense | — | −352 | 292 | — | |
| Interest receivable | 33,057 | −905 | −37,248 | 40,213 | |
| Prepaid expenses | −157,883 | 10,168 | −29,710 | −22,715 | |
| Deferred offering costs | −91,897 | −14,445 | 672,295 | −672,295 | |
| Other assets | 1,625 | — | 2,195 | −5,987 | |
| Accounts payable | −851,805 | 1 | −237,578 | 404,897 | |
| Accrued liabilities | −244,171 | 543,284 | −225,645 | 863,622 | |
| Net cash used in operating activities | −13 | −7 | −4 | −1 | |
| Investment in property and equipment | −5,104 | −6,537 | −3,254 | −2,279 | |
| Net cash used in investing activities | −5,104 | −6,537 | −3,254 | −2,279 | |
| Proceeds from warrant inducements | — | 5 | — | — | |
| Issuance costs from warrant inducement | — | −541,022 | — | — | |
| Proceeds from sale of common stock under ATM | 5 | 5 | — | 7,950 | |
| Issuance costs for sale of common stock under ATM | −271,214 | −337,639 | — | — | |
| Proceeds from the sale of common stock and warrants | 2 | — | — | — | |
| Issuance costs for the sale of common stock and warrants | −291,883 | — | — | — | |
| Proceeds from exercise of warrants | — | 298 | 250,000 | — | |
| Proceeds from exercise of stock options | 48,000 | — | — | — | |
| Net cash provided by financing activities | 7 | 9 | 12 | 1 | |
| Net change in cash and cash equivalents | −6 | 2 | 8 | 32,586 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Cadrenal Therapeutics, Inc.'s CIK number?
Cadrenal Therapeutics, Inc.'s SEC CIK number is 0001937993 (1937993). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Cadrenal Therapeutics, Inc.'s SEC filings?
All of Cadrenal Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Cadrenal Therapeutics, Inc. last report earnings?
Cadrenal Therapeutics, Inc. (CVKD) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-053075). This is Cadrenal Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Cadrenal Therapeutics, Inc.'s most recent earnings 8-K?
Cadrenal Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001213900-26-053075. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Cadrenal Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →